On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...

Scientists in Israel have created the first nano-robot antibodies designed to fight cancer. The first human trial for the new nano-robots will start soon, and it will determine just how effective ...

Researchers leverage snake venom components to develop new hypertension treatments Innovative compounds in snake venom spark ...

In March, iBio collaborated with AstralBio to discover, engineer, and develop antibodies to treat obesity and other cardiometabolic conditions. The antibody, now named IBIO-600, was identified by ...

(NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc. In March, iBio ...

Over the past 10 years, the market for monoclonal antibodies has grown exponentially. This focus issue brings together articles on the basic biology of antibodies and their therapeutic use ...

Proving the efficacy of its new Streamline MP automated aggregation analysis capabilities, Refeyn has also released a tech note discussing “Quantifying antibody aggregation at nano- and ...